Compliance of comprehensive care in children with Duchenne muscular dystrophy: Real-world experience of a pediatric neuromuscular diseases center

Year 2026, Volume: 40 Issue: 1, 65 - 75, 28.01.2026

Çağatay Günay

https://doi.org/10.18614/dehm.1873614

Abstract

ABSTRACT
BACKGROUND
Although international care considerations for Duchenne muscular dystrophy (DMD) were revised in 2018, compliance in clinical practice remains unknown. The objective of this study was to investigate the parental compliance with care considerations in a tertiary hospital in Türkiye.
METHODS
A questionnaire was administered to parents of patients with DMD to assess compliance with recommended frequencies of visits to healthcare providers and clinical tests. The data collected from the questionnaires were analyzed using cross-tables to explore if there were differences between ambulant and non-ambulant patients.
RESULTS
Sixty-one participants completed the questionnaire, most of whom were parents of ambulant patients (n= 44, 72.1%). The majority of parents complied with the recommended frequency of cardiac assessments. However, suboptimal compliance was observed in the rest of the assessments, including the PPSV23 and influenza vaccination rates, which were notably low across all patient groups. Compliance with anthropometric assessments and the use of corticosteroids with proper posology was significantly higher in ambulant patients. Compliance with respiratory and orthopedic evaluations was significantly higher among non-ambulant patients.
CONCLUSION
This study showed several areas in which compliance is insufficient. To improve compliance, future work should focus on home-based assessments, educational programs for patients, parents, and physicians, as well as raising awareness about the importance and timing of recommended vaccinations

Keywords

Compliance , Duchenne muscular dystrophy , delivery of health care , guideline

References

• 1. Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol 2019;32:722–7. https://doi.org/10.1097/WCO.0000000000000739
• 2. Bendixen RM, Senesac C, Lott DJ, Vandenborne K. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health. Health Qual Life Outcomes 2012;10:43. https://doi.org/10.1186/1477-7525-10-43
• 3. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251–67. https://doi.org/10.1016/S1474-4422(18)30024-3
• 4. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018;17:347–61. https://doi.org/10.1016/S1474-4422(18)30025-5
• 5. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 2018;17:445–55. https://doi.org/10.1016/S1474-4422(18)30026-7
• 6. Republic of Türkiye Ministry of Health, National Immunization Program in Türkiye, Available from https://asi.saglik.gov.tr/bagisiklama-programi-ve-asi-takvimi/asi-takvimi.html (Accessed October 24, 2025)
• 7. Heutinck L, Houwen-van Opstal SLS, Krom YD, et al. Compliance to DMD Care Considerations in the Netherlands. J Neuromuscul Dis 2021;8:927–38. https://doi.org/10.3233/JND-210670
• 8. Vry J, Gramsch K, Rodger S, et al. European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences. J Neuromuscul Dis 2016;3:517–27. https://doi.org/10.3233/JND-160185
• 9. Andrews JG, Conway K, Westfield C, et al. Implementation of Duchenne Muscular Dystrophy Care Considerations. Pediatrics 2018;142. https://doi.org/10.1542/peds.2017-4006
• 10. Landfeldt E, Lindgren P, Bell CF, et al. Compliance to Care Guidelines for Duchenne Muscular Dystrophy. J Neuromuscul Dis 2015;2:63–72. https://doi.org/10.3233/JND-140053
• 11. Rodger S, Woods KL, Bladen CL, et al. Adult care for Duchenne muscular dystrophy in the UK. J Neurol 2015;262:629–41. https://doi.org/10.1007/s00415-014-7585-3
• 12. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004;170:456–65. https://doi.org/10.1164/rccm.200307-885ST
• 13. Toussaint M, Davidson Z, Bouvoie V, Evenepoel N, Haan J, Soudon P. Dysphagia in Duchenne muscular dystrophy: practical recommendations to guide management. Disabil Rehabil 2016;38:2052–62. https://doi.org/10.3109/09638288.2015.1111434
• 14. Kraus D, Wong BL, Horn PS, Kaul A. Constipation in Duchenne Muscular Dystrophy: Prevalence, Diagnosis, and Treatment. J Pediatr 2016;171:183–8. https://doi.org/10.1016/j.jpeds.2015.12.046
• 15. Borrelli O, Salvia G, Mancini V, et al. Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. Am J Gastroenterol 2005;100:695–702. https://doi.org/10.1111/j.1572-0241.2005.41303.x
• 16. Lamb MM, West NA, Ouyang L, et al. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy. J Pediatr 2016;173:207-213.e3. https://doi.org/10.1016/j.jpeds.2016.02.067
• 17. West NA, Yang ML, Weitzenkamp DA, et al. Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J Pediatr 2013;163:1759-1763.e1. https://doi.org/10.1016/j.jpeds.2013.08.004
• 18. Colvin MK, Poysky J, Kinnett K, et al. Psychosocial Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics 2018;142:S99–109. https://doi.org/10.1542/peds.2018-0333L
• 19. Saito T, Kawai M, Kimura E, et al. Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan. Neuromuscul Disord 2017;27:107–14. https://doi.org/10.1016/j.nmd.2016.11.012
• 20. Biggar WD, Skalsky A, McDonald CM. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy. J Neuromuscul Dis 2022;9:463–76. https://doi.org/10.3233/JND-210776
• 21. Griggs RC, Herr BE, Reha A, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 2013;48:27–31. https://doi.org/10.1002/mus.23831
• 22. Centers for Disease Control and Prevention. Pneumococcal Vaccine Recommendations. Updated October 26, 2024. Available from: https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html (Accessed October 24, 2025)